In Vitro Susceptibility of Cytomegalovirus Isolates from Immunocompromised Patients to Acyclovir and Ganciclovir
Overview
Microbiology
Pathology
Authors
Affiliations
Fifty-four isolates of cytomegalovirus (CMV) from 25 immunocompromised patients with CMV infections were examined in a plaque reduction assay to determine in vitro susceptibilities to both acyclovir and ganciclovir. Isolates were approximately 25-fold more sensitive to ganciclovir than to acyclovir. The mean +/- SD ID50 for all isolates to acyclovir was 63.1 +/- 30.2 microM, (median, 52.3 microM; range, 16.7-146.4 microM). The mean ID50 for all isolates to ganciclovir was 2.50 +/- 1.27 microM, (median, 2.15 microM; range, 0.65-7.11 microM). Exposure to acyclovir or ganciclovir for periods of 2-5 wk did not alter the mean susceptibility of clinical isolates. However, one CMV strain isolated from a renal transplant patient after 14 days of acyclovir therapy displayed the lowest susceptibility of all strains tested (acyclovir 146.4 microM; ganciclovir 7.11 microM) and may represent selection of a resistant virus population.
Chou S Antiviral Res. 2021; 195:105181.
PMID: 34560144 PMC: 8578386. DOI: 10.1016/j.antiviral.2021.105181.
Vezina H, Brundage R, Balfour Jr H Br J Clin Pharmacol. 2014; 78(2):343-52.
PMID: 24528138 PMC: 4137826. DOI: 10.1111/bcp.12343.
Tseng A, Foisy M Can J Infect Dis. 2012; 7(3):183-94.
PMID: 22514437 PMC: 3327402. DOI: 10.1155/1996/780831.
Perrottet N, Decosterd L, Meylan P, Pascual M, Biollaz J, Buclin T Clin Pharmacokinet. 2009; 48(6):399-418.
PMID: 19650679 DOI: 10.2165/00003088-200948060-00006.
Mori T, Aisa Y, Shimizu T, Nakazato T, Yamazaki R, Ikeda Y Int J Hematol. 2006; 83(3):266-70.
PMID: 16720561 DOI: 10.1532/IJH97.E0523.